LGVN Q4 2024 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$603,000+857.1% YoY

Gross Profit

$530,00087.9% margin

Operating Income

-$4M-710.0% margin

Net Income

-$4M-676.8% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-22.0%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$26M

Total Liabilities

$4M

Stockholders' Equity

$22M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$603,000	$63,000	+857.1%
Gross Profit	$530,000	-$2,000	+26600.0%
Operating Income	-$4M	-$5M	+21.3%
Net Income	-$4M	-$6M	+32.3%